Ivosidenib
艾伏尼布IDH1 inhibitor whose 2026 NRDL payment scope expands beyond relapsed/refractory AML to cover first-line IDH1-mutated AML combined with azacitidine.
China Approval (NMPA)
Approved- Approval Number(s)
- 国药准字HJ20220002
- Initial Approval Date
- Jan 30, 2022
- Notice Published
- Feb 9, 2022
- MAH
- Servier Pharmaceuticals LLC (施维雅药厂有限责任公司)
- Approved Scope
- Initial approval for adult relapsed or refractory AML with a susceptible IDH1 mutation; later expanded to first-line IDH1-mutated AML in combination with azacitidine.
National Reimbursement
Announced · Effective Jan 1, 2027- 2026 Edition Entry
- Negotiated #298 · Class B
- Agreement Period
- 2027-01-01 to 2027-12-31
- Payment Standard
- * Confidential (marked with asterisk in NHSA PDF)
- 2026 Payment Scope
- Expanded to 2 indications: (1) Adult r/r IDH1-mutated AML; (2) First-line newly diagnosed IDH1-mutated AML in combination with azacitidine for patients aged ≥75 or ineligible for intensive induction chemotherapy.
- 限:1.携带易感异柠檬酸脱氢酶-1(IDH1)突变的复发性或难治性急性髓系白血病(AML)成人患者;2.联合阿扎胞苷用于携带易感异柠檬酸脱氢酶-1(IDH1)突变,因合并症无法使用强诱导化疗或者年龄≥75岁的新诊断急性髓系白血病(AML)患者。
Commercial Insurance List
Not ListedNot listed in the 2025 or 2026 NHSA Commercial Health Insurance Innovative Drug List.
2025 vs 2026 NRDL Payment Scope Comparison
Restricted to adults with relapsed or refractory AML with a susceptible IDH1 mutation.
限诊断为携带易感异柠檬酸脱氢酶-1(IDH1)突变的复发性或难治性急性髓系白血病(AML)成人患者。
Expanded to 2 indications: (1) Adult r/r IDH1-mutated AML; (2) First-line newly diagnosed IDH1-mutated AML in combination with azacitidine for patients aged ≥75 or ineligible for intensive induction chemotherapy.
限:1.携带易感异柠檬酸脱氢酶-1(IDH1)突变的复发性或难治性急性髓系白血病(AML)成人患者;2.联合阿扎胞苷用于携带易感异柠檬酸脱氢酶-1(IDH1)突变,因合并症无法使用强诱导化疗或者年龄≥75岁的新诊断急性髓系白血病(AML)患者。
Approved Products, Dosage Forms & Approval Numbers
1 verified NMPA record| Approval No. | Dosage Form & Strength | Event & Scope | Approval / Notice Date | MAH & Source |
|---|---|---|---|---|
| 国药准字HJ20220002 | Tablet (片剂) 250mg | Initial Approval Initial approval for adult relapsed or refractory AML with a susceptible IDH1 mutation; later expanded to first-line IDH1-mutated AML in combination with azacitidine. 首发获批用于携带易感IDH1突变的复发或难治性急性髓系白血病(AML)成人患者;后续扩展至联合阿扎胞苷一线治疗新诊断IDH1突变AML。 | Approved: 2022-01-30 Published: 2022-02-09 | Servier Pharmaceuticals LLC |
Change Timeline
- (2027-01-01)Basic NRDL· Catalog published: Nov 14, 2026
2026 NRDL · Payment Scope Updated
Expanded beyond r/r IDH1-mutated AML in 2025 (#258) to add first-line newly diagnosed IDH1-mutated AML combined with azacitidine (age ≥75 or intensive-chemo ineligible) in 2026 (#298).
Chinese original: 支付范围新增联用阿扎胞苷一线治疗≥75岁或不耐受强诱导化疗的新诊断IDH1突变AML患者(原2025版仅限复发/难治AML)。
NHSA · PDF p.149Verified 2026-11-20 - (2022-01-30)NMPA Approval· Notice published: Feb 9, 2022
NMPA Initial Marketing Approval (国药准字HJ20220002 · 250mg)
Initial approval for adult relapsed or refractory AML with a susceptible IDH1 mutation; later expanded to first-line IDH1-mutated AML in combination with azacitidine.
Chinese original: 首发获批用于携带易感IDH1突变的复发或难治性急性髓系白血病(AML)成人患者;后续扩展至联合阿扎胞苷一线治疗新诊断IDH1突变AML。
NMPA · NMPA Registration HJ20220002Verified 2026-11-21
Verified Names & Aliases
Every English INN, Chinese generic name, brand name, and R&D code is recorded with its source.
Primary Sources for This Record
- NHSAPublished 2026-11-14国家基本医疗保险、生育保险和工伤保险药品目录(2026年)Retrieved 2026-11-20
- NHSAPublished 2025-12-07国家基本医疗保险、生育保险和工伤保险药品目录(2025年)Retrieved 2026-11-20 · 医保发〔2025〕33号附件
- NMPA国家药品监督管理局政务服务门户与药品查询Retrieved 2026-11-20
- WHO世界卫生组织国际非专利药名(INN)指南Retrieved 2026-11-20